Mechanism overviews · 29 papers
Peptidoteca
Readypep ↗
↳ Referencia de Péptidos
Metabolic

Retatrutide

También conocido como: LY3437943 · GGG tri-agonist

An investigational triple-receptor agonist studied in metabolic-research literature.

Written by Peptidoteca Research Desk·Reviewed by Peptidoteca Research Desk·Last reviewed 2026-06-14·4 sources

§ In brief

Retatrutide (also known as LY3437943, GGG tri-agonist) is an investigational triple-receptor agonist studied in metabolic-research literature. It is supplied for laboratory research use only and is not approved for human or veterinary use. Its full amino-acid sequence is not characterised in this reference.

What is Retatrutide?

An investigational triple-receptor agonist studied in metabolic-research literature.

Retatrutide is catalogued here as a reference compound for metabolic-regulation research. The entry covers its chemical identity and the public databases that describe it; it is not a usage guide.

How is Retatrutide studied?

Retatrutide appears in the metabolic-regulation literature, primarily in in-vitro and preclinical (animal) models. This page indexes 4 primary papers on Retatrutide, each tagged with its study type below. Peptidoteca summarizes the proposed mechanism class and the primary sources rather than human outcomes; for the wider library, see the research library.

Is Retatrutide approved for human use?

No. Retatrutide is supplied for laboratory (in-vitro) research use only. It is not approved by the FDA or any comparable regulator for human or veterinary use, and nothing on this page constitutes medical advice, dosing guidance or a treatment recommendation.

What are the research limitations?

Most available evidence for Retatrutide is preclinical — in-vitro and animal models — and findings in those models do not establish efficacy or safety in humans. Human clinical data is limited or absent, and Retatrutide is not an approved drug. Treat the literature as mechanistic research, not clinical guidance.

§ Primary literature

  1. 1.Briand F (2026). Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models. Obesity (Silver Spring).Rodent studyIn preclinical diet-induced obese MASH mouse and hamster models, the triple GIP/GLP-1/glucagon receptor agonist retatrutide was reported to reduce body weight, hepatic steatosis and liver triglycerides, and HOMA-IR insulin resistance, with changes in food intake. Findings are limited to these animal models and do not establish human efficacy.
  2. 2.Perez-Tilve D (2026). GIPR:GCGR co-agonism restores normal weight in obese rodents. Molecular Metabolism.Rodent studyIn this rodent study, the GLP-1R:GIPR:GCGR triagonist retatrutide was reported to normalize body weight in diet-induced obese GLP-1R-knockout mice, indicating retatrutide-driven weight reduction can occur without functional GLP-1 receptor signaling; a GIPR:GCGR co-agonist lacking GLP-1 activity lowered excess body weight comparably.
  3. 3.Li Q (2026). Multi-omic profiling reveals Retatrutide alleviates adipose tissue fibrosis via metabolic reprogramming and tissue repair. Diabetology & Metabolic Syndrome.Rodent studyIn a high-fat-diet mouse model, multi-omic profiling reported that the GIP/GLP-1/glucagon triple agonist retatrutide was associated with reduced adipose-tissue fibrosis — downregulated inflammatory/fibrotic pathways and upregulated reparative signaling — alongside metabolic reprogramming toward fatty-acid oxidation and improved mitochondrial function.
  4. 4.Ganamurali N (2026). The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities. Clinical Pharmacology in Drug Development.ReviewThis review characterizes retatrutide (LY3437943) in the literature as a single-molecule triple receptor agonist acting on the GLP-1, GIP, and glucagon receptors, situating it within the broader development of multi-hormonal peptide pharmacology described for obesity and cardiometabolic comorbidities.
Compound spec
Sequence not publicly characterised
ClassMetabolic
CAS2381089-83-2
Research vial20 / 40 mg

Solo para investigación in-vitro. No es consejo médico, clínico ni de dosificación.